Skip to content

Rhythm Pharmaceuticals

US · RYTM #1874 by market cap Listed 2017
112.36 -4.44 -3.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 15 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.9 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
116.11% +1.91pp
Institutions
406 +15
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund71.93%
Hedge Fund18.70%
VC/PE Fund16.04%
Public Company4.84%
Private Company2.37%
Sovereign Wealth Fund0.99%
Individual/Insider0.78%
Government Pension Fund0.60%
Family Office/Trust0.34%

Top holders as of 2026-06-30

RA Capital Management, L.P. 9.62% · 6.67M sh
BlackRock 8.62% · 5.98M sh
Baker Bros. Advisors LP 8.08% · 5.60M sh
PRIMECAP Management Company 4.57% · 3.17M sh
Vanguard Portfolio Management, LLC 4.54% · 3.15M sh
Vanguard Capital Management, LLC 4.33% · 3.01M sh
State Street Global Advisors 3.81% · 2.64M sh
Perceptive Advisors LLC 3.73% · 2.59M sh
T. Rowe Price Group, Inc. 3.70% · 2.57M sh
J.P. Morgan Asset Management, Inc. 3.69% · 2.56M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 28 buys · 22 sells

NameRoleStake
David Meeker Chairperson & CEO 0.35%
Hunter Smith Chief Financial Officer 0.16%
Yann Mazabraud Executive VP & Head of International 0.08%
Pamela Cramer Former Chief Human Resources Officer 0.04%
Edward Mathers Former Lead Independent Director 0.03%
Joseph Shulman Chief Technology Officer 0.02%
Stuart Arbuckle Independent Director 0.02%
Christophe Jean Independent Director 0.02%
David W. McGirr Independent Director 0.02%
Jennifer Good Independent Director 0.02%
Lynn Tetrault Lead Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-13 David Meeker Chairperson & CEO Derivative Exercise and Sale -50,000 $6.05–105.19
2026-08-30 Hunter Smith Chief Financial Officer Automatic Disposition -5,587 $106.20
2026-08-30 Hunter Smith Chief Financial Officer Derivative Exercise and Sale -57,187 $25.79–106.20
2026-08-16 Manher Joshi Chief Medical Officer Other Derivative Acquisition +25,000 --
2026-08-16 Manher Joshi Chief Medical Officer Other Derivative Acquisition +50,000 $115.44
2026-08-12 Joseph Shulman Chief Technology Officer Automatic Disposition -3,055 $119.75
2026-08-12 Joseph Shulman Chief Technology Officer Derivative Exercise and Sale -2,024 $6.80–119.75
2026-08-12 Alastair Garfield Chief Scientific Officer Automatic Disposition -7,763 $116.11–119.17
2026-08-12 Jennifer Lee Executive VP & Head of North America Automatic Disposition -19,233 $117.38
2026-08-12 Jennifer Lee Executive VP & Head of North America Derivative Exercise and Sale -56,601 $6.80–117.38
2026-08-11 Yann Mazabraud Executive VP & Head of International Automatic Disposition -10,375 $117.47
2026-08-11 Yann Mazabraud Executive VP & Head of International Derivative Exercise and Sale -46,625 $6.80–117.47
2026-08-10 Pamela Cramer Former Chief Human Resources Officer Intent to Sell (Form 144) -11,406 $115.48
2026-08-09 Pamela Cramer Former Chief Human Resources Officer Intent to Sell (Form 144) -3,520 $115.63
2026-06-30 Alastair Garfield Chief Scientific Officer Derivative Exercise and Sale -2,150 $110.41
2026-06-30 Alastair Garfield Chief Scientific Officer Derivative Exercise and Retained +2,295 --
2026-06-23 Jennifer Good Independent Director Other Derivative Acquisition +2,324 --
2026-06-23 Jennifer Good Independent Director Other Derivative Acquisition +3,691 $107.55
2026-06-23 David W. McGirr Independent Director Other Derivative Acquisition +2,324 --
2026-06-23 David W. McGirr Independent Director Other Derivative Acquisition +3,691 $107.55

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Rhythm Pharmaceuticals discussion 0 comments

Add a comment